Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

Key Points

  • The intersection between genomics and personalized medicine is in an early stage. Challenges to applying the principles of evidence-based medicine (EBM) to the assessment of genomics include the rapid pace of technology advancement, the rarity of most monogenic conditions, and the complexity of human genetic variation underlying common conditions.

  • Analytic validity, clinical validity, and clinical utility are important concepts related to the performance of molecular diagnostic testing. Analytic validity describes the ability of a test to reliably detect the presence of a given genomic variation or biomarker, whereas clinical validity describes the relationship of the variant or maker with a trait or disease. Clinical utility is a term describing the ability of a genomic technology to improve health outcomes.

  • The United States Preventive Services Task Force (USPSTF) and Evaluation of Genomic Applications in Practice and Prevention (EGAPP) are developers of rigorous evidence-based guidelines for genomic tests and interventions. Insurer technology assessment groups, professional societies, and disease advocacy organizations are also valuable sources of evidence-based recommendations; however, the rigor of the methodology employed in guideline development and the evidence base supporting these recommendations can be variable.


The intersection of genomic technologies with mainstream health care is growing exponentially. This is occurring at a time where there is a tremendous amount of scrutiny regarding healthcare costs. This is particularly true from public funders (particularly state Medicaid programs) where budget shortfalls are prompting elimination of some traditional services. It is not surprising that health professionals, insurers, and the public are viewing all new technologies through a lens of value—that is, the extent to which resources invested yield measurable improvements in health outcomes. The paradigm of EBM offers approaches for evaluating the benefits and harms of any new technology entering health care, and increasingly these precepts are being applied to evaluate genomic technologies.

Evidence-Based Medicine Versus Genomic Medicine

“EBM is...the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of the individual patient. It means integrating individual clinical expertise with the best available external clinical evidence from systematic research.” (David Sackett et al., 1996)

This definition of EBM, penned by a founding father of the movement, provides a brief grounding in the major tenets of the field. As a discipline, EBM affords a rigorous approach for ordering, digesting, assessing, and succinctly disseminating the vast amount of knowledge available regarding healthcare technologies. Functionally, EBM is often employed to dissect a disparate knowledge base to yield a dichotomous yes or no answer regarding the value of using a particular technology for a well-defined purpose in health care. EBM is a relatively new field; many of the concepts and tools of EBM were pioneered by individuals at McMaster University in the late 1980s. In the United States, perhaps the pre-eminent organization basing its work on EBM is the United States Preventive Services ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.